###begin article-title 0
Associations of Uric Acid with Polymorphisms in the delta-Aminolevulinic Acid Dehydratase, Vitamin D Receptor, and Nitric Oxide Synthase Genes in Korean Lead Workers
###end article-title 0
###begin p 1
Current address: Department of Medicine, York Hospital, York, PA.
###end p 1
###begin p 2
The authors declare they have no competing financial interests.
###end p 2
###begin p 3
###xml 612 616 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 654 658 650 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 689 692 685 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 944 952 930 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS Asp</italic>
###xml 1020 1027 1006 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glu/Glu</italic>
###xml 1090 1094 1074 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 1254 1261 1238 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 1349 1356 1333 1340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 1461 1466 1445 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR B</italic>
###xml 1536 1538 1520 1522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 922 934 <span type="species:ncbi:9606">Participants</span>
###xml 1319 1331 <span type="species:ncbi:9606">participants</span>
###xml 1514 1526 <span type="species:ncbi:9606">participants</span>
Recent research suggests that uric acid may be nephrotoxic at lower levels than previously recognized and that it may be one mechanism for lead-related nephrotoxicity. Therefore, in understanding mechanisms for lead-related nephrotoxicity, it would be of value to determine whether genetic polymorphisms that are associated with renal outcomes in lead workers and/or modify associations between lead dose and renal function are also associated with uric acid and/or modify associations between lead dose and uric acid. We analyzed data on three such genetic polymorphisms: delta-aminolevulinic acid dehydratase (ALAD), endothelial nitric oxide synthase (eNOS), and the vitamin D receptor (VDR). Mean (+/- SD) tibia, blood, and dimercaptosuccinic acid-chelatable lead levels were 37.2 +/- 40.4 mug/g bone mineral, 32.0+/- 15.0 g/dL, and 0.77+/- 0.86 mug/mg creatinine, respectively, in 798 current and former lead workers. Participants with the eNOS Asp allele had lower mean serum uric acid compared with those with the Glu/Glu genotype. Among older workers (age >/= median of 40.6 years), ALAD genotype modified associations between lead dose and uric acid levels. Higher lead dose was significantly associated with higher uric acid in workers with the ALAD1-1 genotype; associations were in the opposite direction in participants with the variant ALAD1-2 genotype. In contrast, higher tibia lead was associated with higher uric acid in those with the variant VDR B allele; however, modification was dependent on participants with the bb genotype and high tibia lead levels. We conclude that genetic polymorphisms may modify uric acid mediation of lead-related adverse renal effects.
###end p 3
###begin p 4
###xml 92 107 92 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-ehp0113-001509">Kim et al. 1996</xref>
###xml 109 124 109 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-ehp0113-001509">Lin et al. 1999</xref>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-ehp0113-001509">2003</xref>
###xml 132 151 132 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-ehp0113-001509">Muntner et al. 2003</xref>
###xml 153 171 153 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-ehp0113-001509">Payton et al. 1994</xref>
###xml 173 193 173 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-ehp0113-001509">Staessen et al. 1992</xref>
###xml 195 209 195 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48-ehp0113-001509">Yu et al. 2004</xref>
###xml 243 258 243 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-ehp0113-001509">Lin et al. 2002</xref>
###xml 260 264 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-ehp0113-001509">2001</xref>
###xml 266 285 266 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-ehp0113-001509">Shadick et al. 2000</xref>
###xml 502 521 502 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-ehp0113-001509">Johnson et al. 2003</xref>
###xml 761 779 761 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-ehp0113-001509">Weaver et al. 2005</xref>
###xml 1232 1236 1228 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 1243 1246 1239 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 1288 1291 1284 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1372 1376 1368 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
Increasing evidence suggests that lead exposure may contribute to decreased renal function (Kim et al. 1996; Lin et al. 1999, 2003; Muntner et al. 2003; Payton et al. 1994; Staessen et al. 1992; Yu et al. 2004) and increased uric acid levels (Lin et al. 2002, 2001; Shadick et al. 2000) at lower doses than previously recognized, particularly in susceptible populations. Similarly, an increasing body of literature suggests that uric acid may be nephrotoxic at lower levels than currently appreciated (Johnson et al. 2003). In previous analyses in the same population of lead workers reported here, we found associations between lead dose and increased uric acid in older workers and evidence that uric acid may mediate some lead-related adverse renal effects (Weaver et al. 2005). Therefore, to understand the mechanisms of lead-related nephrotoxicity, it would be helpful to determine whether genetic polymorphisms that are associated with renal outcomes in lead workers and/or modify associations between lead dose and renal function are also associated with uric acid and/or modify associations between lead dose and uric acid. In this study we evaluated three such genetic polymorphisms: delta-aminolevulinic acid dehydratase (ALAD), the BsmI polymorphism of the vitamin D receptor (VDR) gene, and the Glu298Asp polymorphism of the endothelial nitric oxide synthase (eNOS) gene. We examined associations of these polymorphisms and their effect modification on associations of three lead dose biomarkers in models of uric acid in a cross-sectional analysis of data from the first of three evaluations of 798 current and former Korean lead workers in a longitudinal study of the adverse health effects of inorganic lead exposure.
###end p 4
###begin title 5
Materials and Methods
###end title 5
###begin title 6
Study design and population.
###end title 6
###begin p 7
###xml 547 567 547 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-ehp0113-001509">Schwartz et al. 2001</xref>
###xml 569 588 569 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43-ehp0113-001509">Weaver et al. 2003a</xref>
###xml 201 213 <span type="species:ncbi:9606">participants</span>
###xml 839 851 <span type="species:ncbi:9606">participants</span>
We performed a cross-sectional analysis of first evaluation data from 798 current and former lead workers enrolled in a longitudinal study of the adverse health effects of inorganic lead exposure. All participants provided written, informed consent. The study protocol was approved by institutional review boards at the SoonChunHyang University and the Johns Hopkins University Bloomberg School of Public Health. Participation in the study was voluntary, and workers were paid approximately $30 for their time and effort. As previously described (Schwartz et al. 2001; Weaver et al. 2003a), workers were recruited from 26 different facilities including lead battery, lead oxide, lead crystal, and radiator manufactures and secondary lead smelting. No medical exclusionary criteria (e.g., blood pressure, renal disease) were applied. Study participants were not currently occupationally exposed to other known renal toxicants.
###end p 7
###begin title 8
Data collection.
###end title 8
###begin p 9
###xml 178 198 178 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-ehp0113-001509">Schwartz et al. 2001</xref>
###xml 200 219 200 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43-ehp0113-001509">Weaver et al. 2003a</xref>
###xml 531 532 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 545 546 542 543 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 821 833 <span type="species:ncbi:9606">participants</span>
Data collection was completed either at the Institute of Industrial Medicine of the SoonChunHyang University in Chonan or at the study plants, using previously reported methods (Schwartz et al. 2001; Weaver et al. 2003a). Data and biologic specimens collected included a standardized questionnaire on demographics and medical and occupational history; blood pressure; height and weight measurement; a blood specimen [for blood lead, blood urea nitrogen (BUN), serum creatinine, uric acid, and genotyping]; a spot urine sample [for N-acetyl-beta-d-glucosaminidase (NAG), retinol-binding protein (RBP), and creatinine]; and tibia lead concentration. A 4-hr urine collection after oral administration of 10 mg/kg dimercaptosuccinic acid (DMSA) was also obtained to measure DMSA-chelatable lead and creatinine clearance (787 participants completed this collection).
###end p 9
###begin title 10
Laboratory methods.
###end title 10
###begin p 11
###xml 82 102 82 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-ehp0113-001509">Schwartz et al. 2001</xref>
###xml 104 123 104 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43-ehp0113-001509">Weaver et al. 2003a</xref>
###xml 161 175 161 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-ehp0113-001509">Fernandez 1975</xref>
###xml 480 483 480 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">109</sup>
###xml 685 706 685 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38-ehp0113-001509">Todd and Chettle 1994</xref>
###xml 708 729 708 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39-ehp0113-001509">Todd and McNeill 1993</xref>
###xml 872 887 872 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-ehp0113-001509">Kim et al. 1995</xref>
###xml 1161 1184 1161 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25-ehp0113-001509">Parsons and Slavin 1999</xref>
We measured lead biomarkers and renal outcomes using previously reported methods (Schwartz et al. 2001; Weaver et al. 2003a). In brief, blood lead was measured (Fernandez 1975) with a Zeeman background-corrected atomic absorption spectrophotometer (model 8100; Hitachi Ltd. Instruments, Tokyo, Japan) at the Institute of Industrial Medicine, a certified reference laboratory for lead in Korea. Tibia lead was assessed via a 30-min measurement of the left midtibia diaphysis using 109Cd to fluoresce the K-shell X-rays of lead. The lead X-rays were recorded with a radiation detector and then quantified and compared with calibration data to estimate the concentration of lead in bone (Todd and Chettle 1994; Todd and McNeill 1993). All point estimates, including negative values, were retained in the statistical analyses, to minimize bias and to avoid censoring of data (Kim et al. 1995). Urine lead levels in the 4-hr collection were measured at the Wadsworth Center of the New York State Department of Health (Albany, NY, USA) by electrothermal atomic absorption spectrometry with Zeeman background correction (model 4100ZL; Perkin-Elmer, Norwalk, CT, USA) (Parsons and Slavin 1999).
###end p 11
###begin p 12
###xml 526 550 526 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-ehp0113-001509">Cockcroft and Gault 1976</xref>
###xml 692 713 692 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40-ehp0113-001509">Topping et al. (1986)</xref>
We measured BUN, serum creatinine, and uric acid using an automatic chemical analyzer (model TBA 40FR biochemical analyzer; Toshiba, Tokyo, Japan). Urine creatinine was measured with the Sigma kit (Sigma Chemical Company, St. Louis, MO, USA). Measured creatinine clearance was defined as [(urinary creatinine in milligrams per deciliter x urine volume in milliliters) / serum creatinine in milligrams per deciliter] / collection time in minutes. Calculated creatinine clearance was obtained from the Cockcroft-Gault equation (Cockcroft and Gault 1976). We measured NAG using the PPR NAG test kit (PPR Diagnostics, Ltd., London, UK), and RBP was measured using a modification of the method of Topping et al. (1986).
###end p 12
###begin p 13
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 232 237 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1</italic>
###xml 255 260 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 325 329 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 409 429 405 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-ehp0113-001509">Schwartz et al. 1995</xref>
###xml 431 449 427 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46-ehp0113-001509">Wetmur et al. 1991</xref>
###xml 451 470 447 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49-ehp0113-001509">Ziemsen et al. 1986</xref>
###xml 643 646 639 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Msp</italic>
###xml 660 665 656 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 708 712 704 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 976 979 972 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Asp</italic>
###xml 983 984 979 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1051 1069 1047 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-ehp0113-001509">Hibi et al. (1998)</xref>
###xml 1095 1114 1091 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-ehp0113-001509">Weaver et al. 2003b</xref>
###xml 1121 1128 1117 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR Bsm</italic>
###xml 1194 1195 1190 1191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1275 1276 1271 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 1301 1302 1297 1298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1317 1320 1313 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 1444 1465 1440 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32-ehp0113-001509">Schwartz et al. 2000b</xref>
We isolated DNA for genotyping from whole blood samples using the QIAamp blood kit (QIAGEN, Hilden, Germany). The ALAD polymorphism assayed (delta-aminolevulinic acid dehydratase NCBI accession no. AY319481) results in two alleles: ALAD1 and the variant, ALAD2, which has a G-to-C transversion at codon 177. The protocol for ALAD genotyping involved an initial amplification that generated a 916 bp fragment (Schwartz et al. 1995; Wetmur et al. 1991; Ziemsen et al. 1986). A second amplification, using a pair of nested primers (kindly provided by J. Wetmur), generated an 887 bp fragment. The amplified fragment was cleaved at the diagnostic Msp1 site on the ALAD2 allele. The Glu298Asp polymorphism of the eNOS gene (endothelial nitric oxidase synthase; NCBI accession no. X76307) involves a G-to-T transversion at nucleotide position 894 within exon 7, which results in substitution of aspartic acid for glutamic acid at codon 298; the variant allele is referred to as the Asp or T allele. Genotype was determined by a modification of the assay of Hibi et al. (1998) as previously described (Weaver et al. 2003b). The VDR BsmI polymorphic site in intron 8 [vitamin D (1,25-dihydroxyvitamin D3) receptor; NCBI accession no. AY342401] consists of the common allele, denoted b, and a variant, denoted B, in which the BsmI restriction enzyme site is absent. Amplification used primers originating in exon 7 and intron 8 as previously published (Schwartz et al. 2000b).
###end p 13
###begin title 14
Statistical analysis.
###end title 14
###begin p 15
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 72 75 72 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 195 198 195 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
The primary goals of our analysis were to examine associations of ALAD, VDR, and eNOS genotype with uric acid in lead workers while controlling for other covariates and to evaluate whether ALAD, VDR, and eNOS genotypes modified associations between the lead dose biomarkers (tibia lead, blood lead, DMSA-chelatable lead) and uric acid while controlling for other covariates. Statistical analysis was completed using SAS software, version 8.2 (SAS Institute, Cary, NC, USA).
###end p 15
###begin p 16
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 481 488 481 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 558 565 558 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 682 685 682 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 687 689 687 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BB</italic>
###xml 694 696 694 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 702 706 702 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 708 715 708 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glu/Asp</italic>
###xml 720 727 720 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Asp/Asp</italic>
###xml 1391 1409 1391 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-ehp0113-001509">Weaver et al. 2005</xref>
###xml 1781 1799 1781 1799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-ehp0113-001509">Weaver et al. 2005</xref>
###xml 459 471 <span type="species:ncbi:9606">participants</span>
###xml 540 552 <span type="species:ncbi:9606">participants</span>
###xml 981 993 <span type="species:ncbi:9606">participants</span>
Initially, we examined variable distributions. The distributions of NAG and RBP showed departures from normality and were thus ln-transformed; the adequacy of this transformation was subsequently confirmed by examination of residuals from the final regression models. Linear regression modeling with a dichotomous genotype variable was used to compare uric acid by genotype, while controlling for the same covariates used in the interaction models. For ALAD, participants with the ALAD1-2 genotype were compared with the reference group of participants with ALAD1-1 genotype. Because of small numbers, all analyses combined homozygous and heterozygous variant genotype carriers for VDR (BB and Bb) and eNOS (Glu/Asp and Asp/Asp). Linear regression modeling with genotype and lead variable cross-product terms was used to evaluate effect modification by genotype on associations between lead biomarkers and uric acid. Models with tibia lead were repeated after removal of data from participants with the common allele whose tibia lead levels were higher than the range in those with the variant allele. Covariate selection for final regression models used a priori variables [age, sex, body mass index (BMI; defined as weight in kilograms divided by the square of height in meters)] in modeling that included other biologically relevant variables in separate models, as previously described (Weaver et al. 2005). Covariates retained included age, sex, BMI, categorical alcohol consumption (current, former, never), and, when noted in specific models, systolic blood pressure and serum creatinine. Models are presented with and without these last two variables because their interrelatedness with lead dose and uric acid suggests that neither modeling approach is entirely adequate (Weaver et al. 2005). Continuous independent variables were centered at the mean.
###end p 16
###begin p 17
###xml 122 140 122 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-ehp0113-001509">Weaver et al. 2005</xref>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 518 521 518 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 708 715 708 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 768 774 768 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR bb</italic>
###xml 785 806 785 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-ehp0113-001509">Schwartz et al. 2000a</xref>
###xml 943 950 943 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 951 957 951 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR Bb</italic>
###xml 961 963 961 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BB</italic>
###xml 1196 1203 1196 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 1204 1210 1204 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR bb</italic>
###xml 1229 1236 1229 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 1237 1243 1237 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR Bb</italic>
###xml 1247 1249 1247 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BB</italic>
###xml 1353 1360 1353 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 1365 1371 1365 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR bb</italic>
###xml 556 568 <span type="species:ncbi:9606">participants</span>
###xml 881 893 <span type="species:ncbi:9606">participants</span>
###xml 1174 1186 <span type="species:ncbi:9606">participants</span>
###xml 1331 1343 <span type="species:ncbi:9606">participants</span>
Because effect modification by age on associations between lead biomarkers and uric acid was observed in this population (Weaver et al. 2005), we dichotomized the population by median age and repeated both types of models described above (main effect and interaction) to evaluate associations of genotype in models of uric acid and effect modification by genotype on associations between lead biomarkers and uric acid in different age groups. Last, a model that included cross-products of tibia lead and combined ALAD/VDR genotype subsets was evaluated in participants in the older half of the population to determine if the genotype association previously reported in this population (lead workers with the ALAD1-1 genotype were statistically less likely to have the VDR bb genotype; Schwartz et al. 2000a) was a factor in the effect modification observed in this study. Only two participants in the older age group had both variant alleles (ALAD1-2/VDR Bb or BB), which precluded meaningful analysis of this group; this subset was removed from the model. The final model assessed differences in the slopes of the relations between tibia lead and uric acid in the group of participants with the ALAD1-2/VDR bb genotypes and the ALAD1-1/VDR Bb or BB genotypes, in separate cross-product terms, compared with the reference group of participants with the ALAD1-1 and VDR bb genotypes.
###end p 17
###begin p 18
###xml 25 44 25 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43-ehp0113-001509">Weaver et al. 2003a</xref>
###xml 165 178 165 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45-ehp0113-001509">Weisberg 1985</xref>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 254 255 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 512 526 512 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-ehp0113-001509">Cleveland 1979</xref>
As in previous analyses (Weaver et al. 2003a), we evaluated models for linear regression assumptions and the presence of outlying points using added variable plots (Weisberg 1985), which are graphical summaries of the relation between y and a particular x adjusted for the other covariates. For each plot, two lines were overlaid: the regression line, and a line determined by a scatter plot smoothing method (lowess) that calculates a locally weighted least squares estimate for each point in the scatter plot (Cleveland 1979). This allows an examination of the data for outliers that are overly influential, as evidenced by inconsistency between the lowess and regression lines. When warranted, models were repeated without outliers. Models were also assessed for collinearity by examining variance inflation factors and conditional indices.
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
Selected demographics, exposure, and health outcome measures.
###end title 20
###begin p 21
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 99 106 99 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-ehp0113-001509">Table 1</xref>
###xml 113 116 113 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 143 145 143 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 165 167 165 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BB</italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 218 225 218 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glu/Asp</italic>
###xml 245 252 245 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Asp/Asp</italic>
###xml 371 378 369 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-ehp0113-001509">Table 1</xref>
###xml 525 532 523 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-ehp0113-001509">Table 2</xref>
###xml 21 33 <span type="species:ncbi:9606">participants</span>
###xml 191 203 <span type="species:ncbi:9606">participants</span>
A total of 79 (9.9%) participants were heterozygous for the ALAD2 allele, and none was homozygous (Table 1). For VDR, 85 (10.7%) were genotype Bb, and 4 (0.5%) were BB. For eNOS, 114 (14.4%) participants were genotype Glu/Asp, and 6 (0.7%) were Asp/Asp. Mean (+/- SD) and frequencies for selected demographic, exposure, and outcome variables are presented by genotype in Table 1. Mean uric acid was normal in all genotype subsets. Medians for selected measures are presented by genotype in groups dichotomized by median age (Table 2).
###end p 21
###begin title 22
ALAD.
###end title 22
###begin p 23
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 266 267 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 332 339 329 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 362 363 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 402 409 399 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 539 546 536 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 634 641 631 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3-ehp0113-001509">Table 3</xref>
###xml 773 780 770 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3-ehp0113-001509">Table 3</xref>
###xml 806 814 803 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-ehp0113-001509">Figure 1</xref>
###xml 940 947 937 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3-ehp0113-001509">Table 3</xref>
###xml 1050 1068 1047 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-ehp0113-001509">Weaver et al. 2005</xref>
###xml 1166 1173 1160 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3-ehp0113-001509">Table 3</xref>
###xml 1337 1345 1331 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-ehp0113-001509">Figure 2</xref>
###xml 1393 1400 1387 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3-ehp0113-001509">Table 3</xref>
###xml 1555 1562 1549 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 1674 1681 1667 1674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 1780 1787 1773 1780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 1798 1805 1791 1798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3-ehp0113-001509">Table 3</xref>
###xml 148 160 <span type="species:ncbi:9606">participants</span>
###xml 517 529 <span type="species:ncbi:9606">participants</span>
###xml 926 938 <span type="species:ncbi:9606">participants</span>
###xml 1535 1547 <span type="species:ncbi:9606">participants</span>
###xml 1652 1664 <span type="species:ncbi:9606">participants</span>
Mean uric acid did not differ by ALAD genotype in the total population or in either age group (dichotomized by median age of 40.6 years). Among all participants, ALAD genotype modified the association between blood lead and uric acid. beta-Coefficients were 0.0047 (p = 0.10) for blood lead in the reference group of those with the ALAD1-1 genotype and -0.0158 (p = 0.05) for the cross-product term of ALAD1-2 genotype and blood lead, respectively (thus, the slope of the relation between blood lead and uric acid in participants with the ALAD1-2 genotype was -0.0111). This effect was confined to workers at or above the median age (Table 3, panels 1 and 2, blood lead models). The inverse nature of these associations by genotype, from the blood lead model in panel 2 of Table 3, is shown graphically in Figure 1. Borderline effect modification on the association between tibia lead and uric acid was also observed in older participants (Table 3, panel 2, tibia lead models). Consistent with known mechanisms for the hyperuricemic effects of lead (Weaver et al. 2005), beta-coefficients decreased after additional adjustment for blood pressure and renal function (Table 3, panel 3). Results were similar when calculated creatinine clearance was added to these models instead of serum creatinine (data not shown). Added variable plots (Figure 2) of partial residuals of the tibia lead model (Table 3, panel 2) suggested different tibia lead level ranges by genotype. In order to compare differences over a similar range, data from 43 participants in the ALAD1-1 group with tibia lead levels > 89 mug Pb/g bone mineral (levels above the crude range in participants with the ALAD1-2 genotype) were removed. A positive association between tibia lead and uric acid in those with the ALAD1-1 genotype (Table 3, truncated tibia lead models, panel 2) was then observed.
###end p 23
###begin title 24
VDR.
###end title 24
###begin p 25
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 132 139 132 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4-ehp0113-001509">Table 4</xref>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 298 303 298 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR B</italic>
###xml 403 410 403 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4-ehp0113-001509">Table 4</xref>
###xml 558 565 558 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR bb</italic>
###xml 695 700 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR B</italic>
###xml 737 744 737 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 863 870 863 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 923 929 923 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR bb</italic>
###xml 940 961 940 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-ehp0113-001509">Schwartz et al. 2000a</xref>
###xml 964 971 964 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5-ehp0113-001509">Table 5</xref>
###xml 985 989 985 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 1044 1052 1044 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ehp0113-001509">Figure 3</xref>
###xml 1108 1114 1108 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR bb</italic>
###xml 1213 1219 1212 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR Bb</italic>
###xml 1223 1225 1222 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BB</italic>
###xml 1351 1358 1350 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4-ehp0113-001509">Table 4</xref>
###xml 268 280 <span type="species:ncbi:9606">participants</span>
###xml 531 543 <span type="species:ncbi:9606">participants</span>
###xml 673 685 <span type="species:ncbi:9606">participants</span>
###xml 1086 1098 <span type="species:ncbi:9606">participants</span>
###xml 1195 1207 <span type="species:ncbi:9606">participants</span>
Similar to ALAD, VDR genotype was not associated with uric acid levels, and effect modification was confined to older lead workers (Table 4, tibia lead models, panels 1 and 2). However, in contrast to ALAD, tibia lead was positively associated with uric acid in those participants with the variant VDR B allele, and effect modification on associations between blood lead and uric acid was not observed (Table 4). Modeling that included cross-products of tibia lead with combined genotype subsets compared with a reference group of participants with both the ALAD1-1 and VDR bb genotypes revealed that the opposite direction associations between tibia lead and uric acid in participants with the VDR B allele compared with those with the ALAD1-2 allele were not simply due to the genotype associations previously reported in this population (lead workers with the ALAD1-1 genotype were statistically less likely to have the VDR bb genotype; Schwartz et al. 2000a) (Table 5). Similar to ALAD, the range of tibia lead levels differed by genotype (Figure 3). In contrast, when data from 27 participants with the VDR bb genotype with tibia lead levels > 103 mug Pb/g bone mineral (above the range in participants with VDR Bb or BB genotypes) were removed in order to compare differences over a similar range, effect modification was no longer significant (Table 4, truncated tibia lead models, panel 2).
###end p 25
###begin title 26
eNOS.
###end title 26
###begin p 27
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 24 27 24 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 141 149 141 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS Asp</italic>
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glu/Glu</italic>
###xml 236 237 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 520 524 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 119 131 <span type="species:ncbi:9606">participants</span>
###xml 444 456 <span type="species:ncbi:9606">participants</span>
In contrast to ALAD and VDR, the eNOS genotype was associated with uric acid levels. Mean serum uric acid was lower in participants with the eNOS Asp allele compared with those with the Glu/Glu genotype (beta= -0.1913; SE beta= 0.0932; p = 0.04; adjusted for age, sex, BMI, serum creatinine, systolic blood pressure, and blood lead). Additional modeling in two groups, dichotomized by median age, revealed that this association was confined to participants in the older half of the population. No effect modification by eNOS genotype on associations of lead biomarkers and uric acid was observed.
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 57 60 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 334 342 334 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS Asp</italic>
###xml 399 403 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 607 614 607 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 694 701 694 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 712 715 712 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 845 849 845 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 932 933 932 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1007 1009 1007 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 312 324 <span type="species:ncbi:9606">participants</span>
###xml 468 480 <span type="species:ncbi:9606">participants</span>
###xml 672 684 <span type="species:ncbi:9606">participants</span>
###xml 985 997 <span type="species:ncbi:9606">participants</span>
We evaluated whether polymorphisms in three genes (ALAD, VDR, and eNOS) were associated with uric acid or modified relations of lead biomarkers with uric acid in a cross-sectional analysis of data from the first evaluation in a longitudinal study of 798 current and former Korean lead workers. After adjustment, participants with the eNOS Asp allele had lower mean uric acid. Effect modification by ALAD on associations between lead dose and uric acid was observed in participants whose ages were in the older half of the age range. Higher lead dose was associated with higher uric acid in workers with the ALAD1-1 genotype; associations were in the opposite direction in participants with the ALAD1-2 genotype. VDR genotype modified the association of tibia lead and uric acid, also in the older half of the population. However, in contrast to ALAD, higher tibia lead was associated with higher uric acid in those with the variant B allele, but this effect was dependent on data from participants with the bb genotype and high tibia lead levels.
###end p 29
###begin p 30
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 191 198 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 209 229 209 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-ehp0113-001509">Bergdahl et al. 1997</xref>
###xml 336 343 336 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 382 389 382 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 400 421 400 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-ehp0113-001509">Schwartz et al. 2000a</xref>
###xml 563 568 563 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 629 636 629 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 761 775 760 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-ehp0113-001509">Hu et al. 2001</xref>
###xml 777 794 776 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-ehp0113-001509">Kamel et al. 2003</xref>
###xml 796 814 795 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-ehp0113-001509">Kelada et al. 2001</xref>
###xml 853 857 852 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 966 985 965 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-ehp0113-001509">Fleming et al. 1998</xref>
###xml 987 1004 986 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-ehp0113-001509">Smith et al. 1995</xref>
###xml 1104 1109 1103 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 1147 1161 1146 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-ehp0113-001509">Hu et al. 2001</xref>
###xml 1163 1180 1162 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-ehp0113-001509">Kamel et al. 2003</xref>
###xml 1264 1269 1263 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 1278 1297 1277 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-ehp0113-001509">Fleming et al. 1998</xref>
###xml 1299 1313 1298 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-ehp0113-001509">Hu et al. 2001</xref>
###xml 1315 1335 1314 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-ehp0113-001509">Schwartz et al. 1997</xref>
###xml 1337 1354 1336 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-ehp0113-001509">Smith et al. 1995</xref>
###xml 1437 1442 1436 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 314 326 <span type="species:ncbi:9606">participants</span>
###xml 541 553 <span type="species:ncbi:9606">participants</span>
###xml 1242 1254 <span type="species:ncbi:9606">participants</span>
The ALAD enzyme is a principal lead-binding protein. The isozymes in those with the variant ALAD2 allele bind a greater proportion of blood lead than does the isozyme in individuals with the ALAD1-1 genotype (Bergdahl et al. 1997). In the population that is the focus of this report, mean blood lead was higher in participants with the ALAD1-2 genotype compared with those with the ALAD1-1 genotype (Schwartz et al. 2000a). However, neither tibia nor DMSA-chelatable lead levels differed significantly. Other studies have also reported that participants with the ALAD2 allele have higher blood lead levels than do those with the ALAD1-1 genotype, although studies in populations with mean blood lead levels < 10 mug/dL have generally not reported a difference (Hu et al. 2001; Kamel et al. 2003; Kelada et al. 2001). The limited data on associations of ALAD genotype with bone lead levels reveal no difference in some studies (similar to results in our population) (Fleming et al. 1998; Smith et al. 1995). Lower cortical (tibia) and/or trabecular (patella, calcaneus) bone lead levels in those with the ALAD2 allele have been reported in others (Hu et al. 2001; Kamel et al. 2003). Other toxicokinetic differences have also been reported in participants with the ALAD2 allele (Fleming et al. 1998; Hu et al. 2001; Schwartz et al. 1997; Smith et al. 1995). Overall, these data suggest that tighter binding of lead by the isozymes of the ALAD2 allele decreases lead sequestration in bone. Therefore, the impact on toxicity would depend on whether enzyme bound lead is bioavailable and more toxic than lead that is stored in bone and subsequently released. As a result, toxicity may differ by target organ.
###end p 30
###begin p 31
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 187 206 186 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-ehp0113-001509">Smith et al. (1995)</xref>
###xml 225 226 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 349 354 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 391 398 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 448 464 447 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47-ehp0113-001509">Wu et al. (2003)</xref>
###xml 717 718 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 922 923 916 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 327 339 <span type="species:ncbi:9606">participants</span>
###xml 517 529 <span type="species:ncbi:9606">participants</span>
###xml 853 865 <span type="species:ncbi:9606">participants</span>
Two studies have examined the impact of ALAD genotype on serum uric acid levels in lead exposed populations. In a study of 691 construction workers, whose mean blood lead was 7.8 mug/dL, Smith et al. (1995) found borderline (p = 0.09) higher mean uric acid after adjustment for age, alcohol ingestion, and blood lead in the 96 participants with the ALAD2 allele compared with those with the ALAD1-1 genotype. Effect modification was not evaluated. Wu et al. (2003) found no difference in uric acid by genotype in 709 participants in the Normative Aging Study (mean blood lead = 6.2 mug/dL). However, effect modification by genotype on associations of patella and tibia lead with uric acid of borderline significance (p < 0.1) was observed; beta-coefficients (and slopes) were greater in those with the variant allele. This difference was significant in participants whose patella lead levels were > 15 mug/g bone mineral (p = 0.04).
###end p 31
###begin p 32
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 264 283 264 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-ehp0113-001509">Weaver et al. 2003b</xref>
###xml 565 570 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 808 813 808 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD2</italic>
###xml 844 851 844 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 1078 1082 1078 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 184 196 <span type="species:ncbi:9606">participants</span>
Synthesizing our data with these studies is complicated by the inverse associations we observed. Similar inverse relations between blood and DMSA-chelatable lead and renal outcomes in participants with the ALAD2 allele were previously reported in this population (Weaver et al. 2003b). Because uric acid is filtered at the glomerulus, levels in serum are also influenced by renal function. Therefore, the associations between lead dose and uric acid may be due to the same process causing inverse associations between lead dose and renal function in those with the ALAD2 allele. If this process represents lead-related hyperfiltration, the associations between lead dose and uric acid may become positive as this population ages and eventually, as in the Normative Aging Study, be stronger in those with the ALAD2 allele than in those with the ALAD1-1 genotype. However, several steps are involved in the renal handling of uric acid, including a secretion step in the proximal tubule, which is also thought to be adversely affected by lead. The fact that effect modification by ALAD genotype on associations between tibia lead and uric acid persists after adjustment for renal function suggests that one or more of the other renal handling processes for uric acid are involved. Analysis of our longitudinal data will be very helpful in understanding these complex relations.
###end p 32
###begin p 33
###xml 161 165 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 220 239 220 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-ehp0113-001509">Weaver et al. 2003b</xref>
###xml 539 557 539 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-ehp0113-001509">Weaver et al. 2005</xref>
The potential for uric acid-related nephrotoxicity must be considered in these associations, as well. When previously published models of effect modification by ALAD on associations between lead dose and renal function (Weaver et al. 2003b) were also controlled for uric acid, the effect modification observed remained statistically significant (data not shown), indicating that this effect is not mediated solely through uric acid. However, the current analyses do provide further evidence, in addition to our recently published results (Weaver et al. 2005), that lead dose increases uric acid in these workers, even after control for variables that are both confounders and mediators, such as blood pressure and renal function.
###end p 33
###begin p 34
###xml 305 329 305 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24-ehp0113-001509">Onalaja and Claudio 2000</xref>
###xml 398 399 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 510 512 510 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 523 544 523 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-ehp0113-001509">Schwartz et al. 2000a</xref>
###xml 574 577 574 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 996 998 992 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 1042 1045 1038 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1131 1134 1127 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1220 1239 1216 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-ehp0113-001509">Weaver et al. 2003b</xref>
###xml 1376 1383 1372 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 1392 1394 1388 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 1396 1405 1392 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-ehp0113-001509">Figures 2</xref>
###xml 1410 1411 1406 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ehp0113-001509">3</xref>
###xml 376 388 <span type="species:ncbi:9606">participants</span>
###xml 637 649 <span type="species:ncbi:9606">participants</span>
###xml 829 841 <span type="species:ncbi:9606">participants</span>
###xml 974 986 <span type="species:ncbi:9606">participants</span>
Polymorphisms of the gene encoding for the VDR are of interest in lead-exposed populations because of the importance of the receptor for calcium absorption and bone mineralization. These pathways affect lead absorption from the gastrointestinal tract and may affect lead storage and/or release from bone (Onalaja and Claudio 2000). In the lead workers studied in this report, participants with the B allele were found to have significantly higher blood, tibia, and DMSA-chelatable lead than did those with the bb genotype (Schwartz et al. 2000a). The effect modification of VDR genotype on the association of tibia lead and uric acid in participants who are in the older half of the population may reflect toxicodynamic differences. However, conclusions must be tempered by the fact that this effect is dependent on, at most, 27 participants with tibia lead levels > 103 mug Pb/g bone mineral who reduce the beta estimate of the relation between tibia lead and uric acid in participants with the bb genotype. Further, no associations between VDR genotype and renal outcomes were observed, nor was consistent effect modification by VDR on associations between lead measures and renal outcomes present in this population (Weaver et al. 2003b). Interestingly, the shape of the lowess lines for the relations between tibia lead and uric acid in workers with the common genotypes (ALAD1-1 and VDR bb; Figures 2 and 3) suggests differences at higher tibia lead levels that could reflect survivor bias. We plan to explore this further in longitudinal analyses.
###end p 34
###begin p 35
###xml 37 38 37 38 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 151 152 151 152 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 245 255 245 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-ehp0113-001509">Klahr 2001</xref>
###xml 392 395 392 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Asp</italic>
###xml 404 421 404 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23-ehp0113-001509">Noiri et al. 2002</xref>
###xml 423 440 423 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27-ehp0113-001509">Persu et al. 2002</xref>
###xml 442 462 442 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35-ehp0113-001509">Sofowora et al. 2001</xref>
###xml 541 559 541 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-ehp0113-001509">Golser et al. 2003</xref>
###xml 561 581 561 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-ehp0113-001509">Hoffmann et al. 2005</xref>
###xml 583 597 583 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-ehp0113-001509">Li et al. 2004</xref>
###xml 599 615 599 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21-ehp0113-001509">Moon et al. 2002</xref>
###xml 625 628 625 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Asp</italic>
###xml 752 763 752 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41-ehp0113-001509">Vaziri 2002</xref>
###xml 784 788 784 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 919 920 919 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 939 943 939 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 1022 1025 1022 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Asp</italic>
###xml 1140 1143 1140 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glu</italic>
###xml 1152 1173 1152 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37-ehp0113-001509">Theppeang et al. 2004</xref>
###xml 1266 1270 1266 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 1364 1367 1364 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Asp</italic>
###xml 1377 1396 1377 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-ehp0113-001509">Weaver et al. 2003b</xref>
###xml 1571 1574 1571 1574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Asp</italic>
###xml 1655 1662 1655 1662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glu/Glu</italic>
###xml 1673 1692 1673 1692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-ehp0113-001509">Weaver et al. 2003b</xref>
###xml 1742 1745 1742 1745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Asp</italic>
###xml 1549 1561 <span type="species:ncbi:9606">participants</span>
###xml 1633 1645 <span type="species:ncbi:9606">participants</span>
eNOS catalyzes the transformation of l-arginine to the vasodilator, nitric oxide (NO). Animal models of kidney disease indicate that administration of l-arginine results in decreased renal damage that is thought to be mediated via increased NO (Klahr 2001). The functional significance of the Glu298Asp polymorphism remains uncertain. Some authors have reported decreased NO with the variant Asp allele (Noiri et al. 2002; Persu et al. 2002; Sofowora et al. 2001). However, others have reported no difference in various functional measures (Golser et al. 2003; Hoffmann et al. 2005; Li et al. 2004; Moon et al. 2002). If the Asp allele is ultimately shown to decrease NO, the variant may confer additional risk in lead exposure that also decreases NO (Vaziri 2002). In addition, this eNOS polymorphism may modify lead toxicokinetics. A recent study of data from the third evaluation of the lead workers in this report (n = 652) found that eNOS genotype modified the relation between patella lead and age; workers with the Asp allele had higher increases in patella lead with increasing age than did lead workers who were homozygous for the Glu allele (Theppeang et al. 2004). In the population that is the focus of this report, we found inconsistent associations of eNOS genotype with renal function (higher BUN and measured creatinine clearance in those with the Asp allele) (Weaver et al. 2003b). Effect modification was also noted; longer lead job duration was associated with higher serum creatinine and lower calculated creatinine clearance in participants with the Asp allele and with higher calculated creatinine clearance in participants with the Glu/Glu genotype (Weaver et al. 2003b). The lower uric acid observed in those with the Asp allele may indicate that, if this allele does confer increased renal risk in lead exposed populations, uric acid does not contribute further to that risk.
###end p 35
###begin p 36
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 836 840 836 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 557 569 <span type="species:ncbi:9606">participants</span>
Our data suggest that all three genetic polymorphisms may affect uric acid in these lead workers. However, effect modification by ALAD genotype on associations between lead dose and uric acid was most consistent with the observed effect modification by this genotype on associations between lead dose and renal function. This work also suggests that effect modification by genotype is present only in the older half of the population. However, our ability to explore effect modification by genotype in different age groups is limited by the small number of participants with the variant alleles in these age-stratified models. As a result, even after removal of outliers, most data points in the variant groups are influential. Longitudinal data analysis will be useful, particularly in understanding the inverse associations seen with ALAD.
###end p 36
###begin title 37
References
###end title 37
###begin article-title 38
###xml 64 69 <span type="species:ncbi:9606">human</span>
Lead binding to delta-aminolevulinic acid dehydratase (ALAD) in human erythrocytes
###end article-title 38
###begin article-title 39
Robust locally weighted regression and smoothing scatterplots
###end article-title 39
###begin article-title 40
Prediction of creatinine clearance from serum creatinine
###end article-title 40
###begin article-title 41
Micromethod for lead determination in whole blood by atomic absorption, with use of the graphite furnace
###end article-title 41
###begin article-title 42
Effect of the delta-aminolevulinate dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers
###end article-title 42
###begin article-title 43
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 104 109 <span type="species:ncbi:4932">yeast</span>
Functional characterization of Glu298Asp mutant human endothelial nitric oxide synthase purified from a yeast expression system
###end article-title 43
###begin article-title 44
Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction
###end article-title 44
###begin article-title 45
Endothelial nitric oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics
###end article-title 45
###begin article-title 46
###xml 114 117 <span type="species:ncbi:9606">men</span>
The delta-aminolevulinic acid dehydratase (ALAD) polymorphism and bone and blood lead levels in community-exposed men: the Normative Aging Study
###end article-title 46
###begin article-title 47
Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?
###end article-title 47
###begin article-title 48
Amyotrophic lateral sclerosis, lead, and genetic susceptibility: polymorphisms in the delta-aminolevulinic acid dehydratase and vitamin D receptor genes
###end article-title 48
###begin article-title 49
delta-Aminolevulinic acid dehydratase genotype and lead toxicity: a HuGE review
###end article-title 49
###begin article-title 50
K X-ray fluorescence measurements of bone lead concentration: the analysis of low-level data
###end article-title 50
###begin article-title 51
A longitudinal study of low-level lead exposure and impairment of renal function
###end article-title 51
###begin article-title 52
The role of nitric oxide in hypertension and renal disease progression
###end article-title 52
###begin article-title 53
Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans
###end article-title 53
###begin article-title 54
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency: a randomized, controlled trial
###end article-title 54
###begin article-title 55
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Environmental lead exposure and progression of chronic renal diseases in patients without diabetes
###end article-title 55
###begin article-title 56
Environmental lead exposure and urate excretion in the general population
###end article-title 56
###begin article-title 57
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout
###end article-title 57
###begin article-title 58
Lack of evidence for contribution of Glu298Asp (G894T) polymorphism of endothelial nitric oxide synthase gene to plasma nitric oxide levels
###end article-title 58
###begin article-title 59
Blood lead and chronic kidney disease in the general United States population: results from NHANES III
###end article-title 59
###begin article-title 60
Association of eNOS Glu298Asp polymorphism with end-stage renal disease
###end article-title 60
###begin article-title 61
Genetic susceptibility to lead poisoning
###end article-title 61
###begin article-title 62
Electrothermal atomization atomic absorption spectrometry for the determination of lead in urine: results of an interlaboratory study
###end article-title 62
###begin article-title 63
Low-level lead exposure and renal function in the Normative Aging Study
###end article-title 63
###begin article-title 64
Modifier effect of ENOS in autosomal dominant polycystic kidney disease
###end article-title 64
###begin article-title 65
Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers
###end article-title 65
###begin article-title 66
Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with polymorphisms in the vitamin D receptor and delta-aminolevulinic acid dehydratase genes
###end article-title 66
###begin article-title 67
Associations of delta-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers
###end article-title 67
###begin article-title 68
delta-Aminolevulinic acid dehydratase genotype modifies 4-hour urinary lead excretion after oral administration of dimercaptosuccinic acid
###end article-title 68
###begin article-title 69
Associations of tibial lead levels with BsmI polymorphisms in the vitamin D receptor in former organolead manufacturing workers
###end article-title 69
###begin article-title 70
###xml 90 93 <span type="species:ncbi:9606">men</span>
Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the Normative Aging Study
###end article-title 70
###begin article-title 71
A polymorphism in the delta-aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead
###end article-title 71
###begin article-title 72
In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism
###end article-title 72
###begin article-title 73
Impairment of renal function with increasing blood lead concentrations in the general population
###end article-title 73
###begin article-title 74
Associations of patella lead with polymorphisms in the vitamin D receptor, delta-aminolevulinic acid dehydratase and endothelial nitric oxide synthase genes
###end article-title 74
###begin article-title 75
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
In vivo X-ray fluorescence of lead in bone: review and current issues
###end article-title 75
###begin article-title 76
Measurement of urinary retinol-binding protein by enzyme-linked immunosorbent assay, and its application to detection of tubular proteinuria
###end article-title 76
###begin article-title 77
Pathogenesis of lead-induced hypertension: role of oxidative stress
###end article-title 77
###begin article-title 78
Associations among lead dose biomarkers, uric acid, and renal function in Korean lead workers
###end article-title 78
###begin article-title 79
Associations of lead biomarkers with renal function in Korean lead workers
###end article-title 79
###begin article-title 80
Associations of renal function with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers
###end article-title 80
###begin article-title 81
###xml 121 129 <span type="species:ncbi:9606">children</span>
The delta-aminolevulinate dehydratase polymorphism: higher blood lead levels in lead workers and environmentally exposed children with the 1-2 and 2-2 isozymes
###end article-title 81
###begin article-title 82
A delta-aminolevulinic acid dehydratase (ALAD) polymorphism may modify the relationship of low-level lead exposure to uricemia and renal function: the Normative Aging Study
###end article-title 82
###begin article-title 83
Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study
###end article-title 83
###begin article-title 84
Polymorphism of delta-aminolevulinic acid dehydratase in lead-exposed workers
###end article-title 84
###begin p 85
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
We thank Y.-B. Kim, B.-K. Jang, and G.-S. Lee for assistance with data collection in South Korea and J. Wetmur of the Mount Sinai School of Medicine for providing the nested primers for ALAD genotyping.
###end p 85
###begin p 86
This research was supported by the following grants: ES07198 (B.S.S.), 2 ES07198 (V.M.W.), ES00002 (K.T.K.), and National Research Service Award F30-ES05922-02 (M.E.L.) from the National Institute of Environmental Health Sciences; KRF-2000-00545 (B.-K.L.) from the Korea Research Foundation; ATPM TS288-14/14 (E.K.S.) from the Centers for Disease Control and Prevention; and the Richard Ross Clinician Scientist Award (B.G.J.) from the Johns Hopkins University School of Medicine.
###end p 86
###begin title 87
Figures and Tables
###end title 87
###begin p 88
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 162 169 160 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3-ehp0113-001509">Table 3</xref>
###xml 439 446 437 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 591 598 589 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
###xml 417 429 <span type="species:ncbi:9606">participants</span>
###xml 569 581 <span type="species:ncbi:9606">participants</span>
Plot of model assessing effect modification by ALAD genotype on the association of blood lead and uric acid in Korean lead workers whose ages are >/= 40.6 years (Table 3, panel 2). Regression lines, generated using mean values of covariates in the model (age, sex, BMI, and alcohol use), are overlaid on crude data. The solid regression line represents the adjusted relation between blood lead and uric acid in older participants with the ALAD1-1 genotype (circles); the dashed regression line represents the adjusted relation between blood lead and uric acid in older participants with the ALAD1-2 genotype (stars).
###end p 88
###begin p 89
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 178 185 176 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3-ehp0113-001509">Table 3</xref>
Added variable plot of the model assessing effect modification by ALAD genotype on the association between tibia lead and uric acid in Korean lead workers >/= 40.6 years of age (Table 3, panel 2). For each plot, the regression line (dashed line) and the lowess line (solid line) of the partial residual data points, adjusted for age, sex, BMI, and alcohol use, are overlaid. For ease of interpretation, axes have been scaled so that the plotted residuals are centered around mean uric acid and tibia lead, rather than around zero.
###end p 89
###begin p 90
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 186 193 184 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4-ehp0113-001509">Table 4</xref>
Added variable plot of the model assessing effect modification by VDR genotype on the association between tibia lead and uric acid in Korean lead workers >/= 40.6 years of age (median) (Table 4, panel 2). For each plot, the regression line (dashed line) and the lowess line (solid line) of the partial residual data points, adjusted for age, sex, BMI, and alcohol use, are overlaid. For ease of interpretation, axes have been scaled so that the plotted residuals are centered around mean uric acid and tibia lead, rather than around zero.
###end p 90
###begin p 91
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="tfn2-ehp0113-001509">a</xref>
Selected demographic, exposure, and outcome variables by ALAD, eNOS, and VDR genotype in 798 Korean lead workers.a
###end p 91
###begin p 92
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 16 19 16 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 109 130 109 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-ehp0113-001509">Weaver et al. (2003b)</xref>
ALAD, eNOS, and VDR genotyping were completed on 795, 793, and 798 lead workers, respectively. Modified from Weaver et al. (2003b).
###end p 92
###begin p 93
Values are mean +/- SD unless otherwise noted.
###end p 93
###begin p 94
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 100 103 100 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
Medians of selected demographic, exposure, and outcome variables in Korean lead workers by ALAD and VDR genotype in two groups dichotomized by median age (40.6 years).
###end p 94
###begin p 95
Actual value, not median.
###end p 95
###begin p 96
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
Linear regression models of uric acid, evaluating effect modification by ALAD genotype on associations of blood and tibia lead in two groups of lead workers, dichotomized by median age (40.6 years).
###end p 96
###begin p 97
-, model shown was not adjusted for that covariate. Panels 1 and 2 display results in the younger and older groups, respectively. Panel 3 shows results in the older group after additional control for systolic blood pressure and serum creatinine. Models were also adjusted for sex, BMI, and alcohol use.
###end p 97
###begin p 98
###xml 61 69 61 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ALAD1-1</italic>
Reference category of homozygotes for the common gene allele (ALAD1-1).
###end p 98
###begin p 99
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 449 456 443 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-2</italic>
p-Values for the cross-product terms reflect the statistical significance of the difference between the slopes of the regression line for the variant gene group and the regression line for the reference gene group; slopes in the variant gene group are obtained by adding the beta-coefficient of the cross-product term to the beta-coefficient for the reference category [i.e., the slope of the relation between blood lead and uric acid in those with ALAD1-2 genotype is -0.0085 in panel 2 (0.0127 + -0.0212)].
###end p 99
###begin p 100
Tibia lead levels > 89 mug Pb/g bone mineral were removed from models.
###end p 100
###begin p 101
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
Linear regression models of uric acid, evaluating effect modification by VDR genotype on associations of blood and tibia lead in two groups of lead workers, dichotomized by median age (40.6 years).
###end p 101
###begin p 102
-, model shown was not adjusted for that covariate. Panels 1 and 2 display results in the younger and older groups, respectively. Panel 3 shows results in the older group after additional control for systolic blood pressure and serum creatinine. Models were also adjusted for sex, BMI, and alcohol use.
###end p 102
###begin p 103
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR bb</italic>
Reference category of homozygotes for the common gene allele (VDR bb).
###end p 103
###begin p 104
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 449 455 443 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR Bb</italic>
###xml 459 461 453 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BB</italic>
p-Values for the cross-product terms reflect the statistical significance of the difference between the slopes of the regression line for the variant gene group and the regression line for the reference gene group; slopes in the variant gene group are obtained by adding the beta-coefficient of the cross-product term to the beta-coefficient for the reference category [i.e., the slope of the relation between tibia lead and uric acid in those with VDR Bb or BB genotypes is 0.0130 in panel 2 (-0.0008 + 0.0138)].
###end p 104
###begin p 105
Tibia lead levels > 103 mug Pb/g bone mineral were removed from models.
###end p 105
###begin p 106
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD</italic>
###xml 76 79 76 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
Linear regression model evaluating effect modification by combined ALAD and VDR genotypes on the association between tibia lead and uric acid, in lead workers >/= 40.6 years of age (median).
###end p 106
###begin p 107
Models were also adjusted for sex, BMI, and alcohol use.
###end p 107
###begin p 108
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR bb</italic>
Reference category for homozygotes for both common gene alleles (ALAD1-1 and VDR bb).
###end p 108
###begin p 109
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
p-Values for the cross-product terms reflect the statistical significance of the difference between the slopes of the regression line for the variant gene groups and the regression line for the reference gene group. Slopes in the variant gene groups are obtained by adding the
###end p 109
###begin p 110
###xml 183 190 177 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALAD1-1</italic>
###xml 195 201 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR Bb</italic>
###xml 205 207 199 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BB</italic>
beta-coefficient of the cross-product term to the beta-coefficient for the reference category [i.e., the slope of the relation between tibia lead and uric acid in those with both the ALAD1-1 and VDR Bb or BB genotypes is 0.0132 (-0.0008 + 0.0140)].
###end p 110

